61 results about "Hemorrhagic strokes" patented technology

Disclosed in the present invention are a method and system for predicting a hematoma expansion event of a stroke patient. The method comprises: collecting patient data information, and performing data preprocessing; using an XG-Boost model to calculate the SHAP average value and the contribution degrees of different types of data, and extracting a feature quantity with the highest contribution degree from each type of data; performing multivariate linear regression analysis to obtain the weight of the effect of each type of data on hematoma expansion, and weighting all the feature quantities on the basis of the weight to obtain weighted feature quantities; using an extreme learning machine to predict a hematoma expansion probability; and using a northern goshawk optimization algorithm to search predicted values for the boundary of occurrence of a hematoma expansion event, and verifying the prediction accuracy. The present invention can accurately analyze and predict the expansion risk of hematoma after hemorrhagic stroke, which is crucial to early diagnosis and timely treatment.

The invention provides application of active decapeptide in preparation of a medicine for preventing or treating cerebral apoplexy, and belongs to the technical field of biological medicine, the active decapeptide with the amino acid sequence as shown in SEQ ID NO.1 is applied to prevention or treatment of cerebral apoplexy for the first time, the active decapeptide can effectively inhibit formation of cerebral thrombosis of zebra fish with ischemic cerebral apoplexy, and the active decapeptide can be used for preventing or treating cerebral apoplexy. The brain blood flow supply is recovered; meanwhile, the active decapeptide can significantly reduce the hemorrhagic area and hemorrhagic rate of the zebra fish brain with hemorrhagic stroke, repair brain vascular injury and inhibit the occurrence and development of hemorrhagic stroke. In addition, the active decapeptide has small toxic and side effects, and is of great significance for improving the clinical curative effect of cerebral apoplexy and reducing the medication risk when being used for research and development of novel drugs for resisting cerebral apoplexy.

The present application relates to the technical field of medical devices, in particular to an automatic infusion control method and system based on brain blood flow monitoring, the automatic infusion control method comprising the following steps: step one, monitoring blood flow velocity and pulsatility index of large vessels; step two, comparing real-time blood flow velocity with initial blood flow velocity and real-time pulsatility index with initial pulsatility index respectively; step three, determining based on the comparison results, including: if the real-time blood flow velocity is less than the initial blood flow velocity and the difference between the two is greater than a first threshold, then determining that it is ischemic stroke; if the real-time pulsatility index is greater than the initial pulsatility index and the difference between the two is greater than a second threshold, then determining that it is hemorrhagic stroke; step four, based on the determination results of ischemic stroke or hemorrhagic stroke, using a predetermined infusion mechanism to control infusion. The automatic infusion control method in the present application can improve the infusion timeliness of the existing automatic infusion control system and realize the infusion automation thereof.

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The present invention recognizes that there is a need for the prophylaxis or treatment of Stroke Related Disorders, which includes but is not limited to stroke, ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and related cardiovascular diseases, or combinations thereof, or combinations thereof. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of Stroke Related Disorders using various pharmaceutical compositions. A second aspect of the present invention generally relates to pharmaceutical compositions used for the prophylaxis or treatment of Stroke Related Disorders.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

A low field magnetic resonance imaging (MRI) stroke identification sequence uses an inversion recovery sequence. TE is set to the minimum or near-minimum value achievable by a system to minimize an impact of T2 effect on a signal S. Additionally, it selects combinations of TR values and corresponding TI values to make signal from cerebral hemorrhage appear as high signal, and signals from cerebral infarct tissue and cerebral parenchyma appear as isointense or low signal. This allows for rapid and accurate determination of hemorrhagic stroke and, by utilizing low-field magnetic resonance, enhances the accessibility for patients.

The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of *Barbarea orthoceras Ledeb*, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing, as an active ingredient, a hot water extract of the whole plant of *Barbarea orthoceras Ledeb* having potent thrombin inhibitory and blood coagulation factor inhibitory activities. The extract of *Barbarea orthoceras* (Ledeb) as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.

The present invention relates to a protein for the prevention or treatment of neurological diseases and a pharmaceutical composition containing the same. According to one aspect, the protein or polynucleotide exhibits excellent therapeutic effects in animal models of stroke, cerebral palsy, dementia, Parkinson's disease, and autism, and thus has the effect of being useful for the prevention or treatment of neurological diseases that are difficult to regenerate.

The present invention provides the use of α-asarone in the preparation of a drug for preventing or treating hemorrhagic stroke. The structure of α-asarone is shown in Formula I. It can significantly improve short-term neurological deficits and long-term learning and memory function in model rats, reduce cerebral edema, improve blood-brain barrier permeability, and prevent or alleviate brain tissue atrophy during the recovery period. It has a definite therapeutic effect on animal models of hemorrhagic stroke without significant toxic side effects, and is expected to become a promising drug for the prevention and treatment of hemorrhagic stroke. #imgabs0#

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

Disclosed is the compound of Formula (I), and pharmaceutical salts thereof, for use in the treatment of stroke (e.g. acute ischaemic stroke and haemorrhagic stroke) and post-stroke pain, wherein the compound is administered to a subject less than 6 hours from stroke onset. Also disclosed is the compound for use in preventing or reducing the risk of iatrogenic stroke and pharmaceutical compositions comprising the compound.

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

According to the application of the GLX351322 in preparation of the medicine for preventing and treating the hemorrhagic stroke, the molecular formula of the GLX351322 is C21H25N3O5S, the CAS number of the GLX351322 is 835598-94-2, and the molecular weight of the GLX351322 is 431.51. The administration amount of the GLX351322 is 1-5 mg / kg / d, and the administration mode comprises oral administration, intravenous injection or intravenous drip. According to the application disclosed by the invention, the GLX351322 is injected into a mouse ICH model for treatment, so that the volume of cerebral hematoma of a mouse can be remarkably reduced, oxidative stress and inflammatory response can be inhibited, and ISR-eIF2alpha-ATF4-NOX4-ROS circulation can be blocked, and the GLX351322 is prompted to have a certain prevention and treatment effect on hemorrhagic cerebral apoplexy.

The present invention relates to a pharmaceutical use, of a compound of formula I or a salt thereof, for improving mortality, neurological impairment, and / or daily activity in patients with resuscitated cardiac arrest receiving target temperature management (TTM) for maintaining a temperature between about 32°C and about 36°C, patients with ischemic or hemorrhagic stroke receiving TTM, patients with traumatic brain or spinal cord injury receiving TTM, or patients with hypoxic-ischemic encephalopathy receiving TTM.

The present invention provides the use of α-asarone in the manufacture of a drug for preventing or treating hemorrhagic stroke, the structure of α-asarone is shown in formula I, which significantly improves short-term neurological function deficit and long-term learning memory function in model rats, relieves cerebral edema, improves blood-brain barrier permeability, and prevents or alleviates cerebral tissue atrophy in the recovery period, has obvious therapeutic effect on animal models of hemorrhagic stroke, has no obvious toxicity and side effects, and is expected to be a preventive / treatment drug for hemorrhagic stroke. [Formula 1] JPEG2024512842000012.jpg31163

The invention relates to the technical field of cerebral apoplexy detection and diagnosis, in particular to a cerebral hemorrhage point size analysis method based on multi-scale power spectrum entropy and singular spectrum entropy, which comprises the following steps: acquiring medical image data containing a cerebral hemorrhage area, and preprocessing the medical image data; analyzing the preprocessed image data by using a multi-scale power spectrum entropy algorithm, and extracting power spectrum entropy characteristics of the bleeding point area; and analyzing the preprocessed image data by using a multi-scale singular spectrum entropy algorithm, and extracting power spectrum entropy characteristics of the bleeding point area. According to the method, the power spectrum entropy and the singular spectrum entropy are extracted and calculated from the microwave signals of different hemorrhagic spot sizes in the cerebral hemorrhagic stroke, the microwave signals are analyzed, the cerebral hemorrhagic spots of different sizes can be effectively distinguished, the multi-scale power spectrum entropy and the singular spectrum entropy are taken as features to be substituted into a machine learning algorithm for training, and the cerebral hemorrhagic spot detection accuracy is improved. And the sizes are quickly classified, so that the aim of analyzing the sizes of different bleeding spots is fulfilled.

The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of Acer pseudosieboldianum, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing, as an active ingredient, a hot water extract or ethanol extract of Acer pseudosieboldianum leaves having potent thrombin inhibitory and blood coagulation factor inhibitory activity. The extract of *Acer pseudosieboldianum*, used as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention, exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.

A method for treating brain injury in a subject comprises administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant. The protein variant is delivered systemically and can reduce tissue damage after ischemic brain tissue reperfusion. The methods specifically involve the use of G415R mutants of PKM2 protein variants. The treatment is suitable for brain injury caused by hemorrhagic stroke and ischemic stroke. The PKM2 protein variants are ideally administered intravenously within one hour of reperfusion to maximize their therapeutic efficacy.

Medical diagnostic devices and related methods of use are described in which one or multiple coils in a sensor, each coil connected with an RLC circuit and frequency counter, are held against a patient's head at predetermined cranial locations. Frequencies of the RLC circuit are measured and compared against those taken from known, control heads, to determine whether there is a medical problem and what type of problem. In some instances, too high of frequencies can reveal pooled blood in the head, a sign of hemorrhagic stroke, while too low of frequencies imply lack of blood supply, a sign of ischemic stroke. A head-mountable frame can assist a first responder in securing and guiding the coils and, along with fiducials, allow for automatic comparison of frequencies with the correct control data.

The present invention discloses a method and system for analyzing edema after hemorrhagic stroke and for treatment planning. The method involves collecting and preprocessing edema volume data for each patient at different time points. Then, using a Gaussian fitting algorithm to construct a curve of the edema volume evolution over time and calculating the residual from the actual value, dividing the patients into subgroups using a deep learning clustering algorithm, fitting the edema volume for each subgroup at different time points and calculating the residual from the actual value. The change in edema volume is calculated, trends of change are identified, and the corresponding treatment plans are combined with the corresponding edema evolution trend and analyzed using an association rule algorithm to identify the treatment plan with the highest correlation. The present invention utilizes advanced algorithms to accurately analyze changes in edema volume after hemorrhagic stroke and improve the accuracy of patient prognosis prediction. Detailed analysis of different patient subgroups supports more personalized treatment plans and contributes to improved treatment efficacy.

The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of Euphorbia hypericifolia, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing an extract of Euphorbia hypericifolia as an active ingredient having potent thrombin inhibitory and blood coagulation factor inhibitory activity. The extract of *Euphorbia hypericifolia*, used as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention, exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.

The present invention relates to a pharmaceutical use, of a compound of formula I or a salt thereof, for improving mortality, neurological impairment, and / or daily activity in patients with resuscitated cardiac arrest receiving target temperature management (TTM) for maintaining a temperature between about 32°C and about 36°C, patients with ischemic or hemorrhagic stroke receiving TTM, patients with traumatic brain or spinal cord injury receiving TTM, or patients with hypoxic-ischemic encephalopathy receiving TTM.

The invention discloses an application of curcumin in preparation of a neuroprotective drug for inhibiting ferroptosis, and relates to the technical field of medical application of natural drugs, curcumin is used as an active ingredient for preventing or treating nerve cell injury related to ferroptosis, and comprises an H2O2-induced oxidative stress model and a hemin-induced hemorrhagic stroke model; the optimal window of curcumin in a specific concentration range is defined, efficient and safe neuroprotection is achieved, the high-concentration toxicity risk is avoided, the medication accuracy is improved, curcumin can play a multi-target role, the active oxygen level and lipid peroxidation products in cells can be reduced in a concentration-dependent mode, the glutathione content is up-regulated, and the neuroprotective effect is achieved. According to the curcumin, the expression of GPX4 and xCT key proteins is enhanced, so that the ferroptosis process is synergistically inhibited, the neuroprotection theory of the curcumin is enriched, and a solid foundation is laid for clinical application of the curcumin in diseases such as Alzheimer's disease.

The present invention relates to a stroke differentiation sequence using low-field magnetic resonance imaging, and a device with the differentiation sequence. An inversion recovery sequence is used, and a TE uses the minimum or near-minimum TE value achievable by a system, thereby minimizing the impact of T2 effect on a signal S; moreover, a combination of a TR value and a corresponding TI value is selected, such that the signal of intracerebral hemorrhage is hyperintense, and the signals of cerebral infarct tissue and brain parenchyma are isointense or hypointense, thereby quickly and accurately identifying hemorrhagic stroke; and low-field magnetic resonance imaging is used, thereby achieving higher accessibility for patients.

This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.

The present invention relates to a method for selecting a patient suffering from a stroke for reperfusion therapy, based on determining the levels of retinol binding protein 4 (RBP4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The present invention also relates to a method for differentiating between ischemic stroke and hemorrhagic stroke, and to a kit comprising reagents for performing said methods.

The invention provides an application of a biliverdin reductase inhibitor in preparation of a medicine for treating hemorrhagic stroke, relates to the technical field of biological medicines, and discloses that biliverdin reductase generates pathological nuclear translocation in the hemorrhagic stroke, and a lipid peroxidation pathway is activated through co-localization of the biliverdin reductase and a lipid metabolism key enzyme ACSL4, so that the biliverdin reductase inhibitor can be used for treating the hemorrhagic stroke. The nerve cell ferroptosis is driven; the biliverdin reductase is used as a novel treatment target, and the inhibitor can effectively relieve iron overload, improve lipid peroxidation, recover GPX4 expression and reduce nerve cell ferroptosis by specifically blocking biliverdin reductase expression or nuclear translocation on the premise of not remarkably interfering the physiological cytoplasm antioxidant function of biliverdin reductase. And finally, the neurological impairment of an animal model is remarkably improved, and the method has the clinical safety advantages of mechanism novelty, curative effect verifiability, targeting accuracy and avoidance of high bilirubin toxicity risk.

Disclosed are an analysis method and a system for analysis of and a treatment plan for edema after a hemorrhagic stroke, comprising: collecting edema volume data of each patient at different time points and preprocessing the data; using a Gaussian fitting algorithm to perform fitting, constructing a curve of edema volume progression over time, and calculating a residue between the curve and a true value; dividing patients into multiple subgroups by means of a deep learning clustering algorithm, fitting the edema volume of each subgroup at different time points, and calculating a residue thereof with a true value; calculating a change in edema volume, determining a change trend, combining with a corresponding treatment plan, using an association rule algorithm to analyze a degree of correlation, and identifying a treatment plan having the highest degree of correlation with the edema progression trend. The present invention uses advanced algorithms to accurately analyze changes in edema volume after hemorrhagic stroke, improving the accuracy of predicting patient prognosis. By means of detailed analysis of different patient subgroups, it supports more personalized treatment plans and helps improve treatment effects.